These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36076930)

  • 1. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment.
    Fischer C; Turchinovich A; Feisst M; Riedel F; Haßdenteufel K; Scharli P; Hartkopf AD; Brucker SY; Michel L; Burwinkel B; Schneeweiss A; Wallwiener M; Deutsch TM
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
    Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
    Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.
    Fischer C; Deutsch TM; Feisst M; Rippinger N; Riedel F; Hartkopf AD; Brucker SY; Domschke C; Fremd C; Michel L; Burwinkel B; Schneeweiss A; Turchinovich A; Wallwiener M
    Arch Gynecol Obstet; 2022 Sep; 306(3):875-885. PubMed ID: 35237856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
    Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B
    Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
    Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
    Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-to-mesenchymal transition is associated with a poor prognosis.
    Bulfoni M; Gerratana L; Del Ben F; Marzinotto S; Sorrentino M; Turetta M; Scoles G; Toffoletto B; Isola M; Beltrami CA; Di Loreto C; Beltrami AP; Puglisi F; Cesselli D
    Breast Cancer Res; 2016 Mar; 18(1):30. PubMed ID: 26961140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating microRNAs and treatment response in the Phase II SWOG S0925 study for patients with new metastatic hormone-sensitive prostate cancer.
    Cheng HH; Plets M; Li H; Higano CS; Tangen CM; Agarwal N; Vogelzang NJ; Hussain M; Thompson IM; Tewari M; Yu EY
    Prostate; 2018 Feb; 78(2):121-127. PubMed ID: 29105802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-targeted therapy influences CTC status in metastatic breast cancer.
    Deutsch TM; Riethdorf S; Fremd C; Feisst M; Nees J; Fischer C; Hartkopf AD; Pantel K; Trumpp A; Schütz F; Schneeweiss A; Wallwiener M
    Breast Cancer Res Treat; 2020 Jul; 182(1):127-136. PubMed ID: 32436146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishment of a multimarker qPCR panel for the molecular characterization of circulating tumor cells in blood samples of metastatic breast cancer patients during the course of palliative treatment.
    Bredemeier M; Edimiris P; Tewes M; Mach P; Aktas B; Schellbach D; Wagner J; Kimmig R; Kasimir-Bauer S
    Oncotarget; 2016 Jul; 7(27):41677-41690. PubMed ID: 27223437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection and Characterization of Circulating Tumor Associated Cells in Metastatic Breast Cancer.
    Mu Z; Benali-Furet N; Uzan G; Znaty A; Ye Z; Paolillo C; Wang C; Austin L; Rossi G; Fortina P; Yang H; Cristofanilli M
    Int J Mol Sci; 2016 Sep; 17(10):. PubMed ID: 27706044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Circulating Tumor Cells in Hormone Receptor-positive Metastatic Breast Cancer Patients who Received Letrozole with or Without Bevacizumab.
    Magbanua MJM; Savenkov O; Asmus EJ; Ballman KV; Scott JH; Park JW; Dickler M; Partridge A; Carey LA; Winer EP; Rugo HS
    Clin Cancer Res; 2020 Sep; 26(18):4911-4920. PubMed ID: 32586939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
    Ye Z; Wang C; Wan S; Mu Z; Zhang Z; Abu-Khalaf MM; Fellin FM; Silver DP; Neupane M; Jaslow RJ; Bhattacharya S; Tsangaris TN; Chervoneva I; Berger A; Austin L; Palazzo JP; Myers RE; Pancholy N; Toorkey D; Yao K; Krall M; Li X; Chen X; Fu X; Xing J; Hou L; Wei Q; Li B; Cristofanilli M; Yang H
    Eur J Cancer; 2019 Jan; 106():133-143. PubMed ID: 30528798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes.
    Peeters DJ; van Dam PJ; Van den Eynden GG; Rutten A; Wuyts H; Pouillon L; Peeters M; Pauwels P; Van Laere SJ; van Dam PA; Vermeulen PB; Dirix LY
    Br J Cancer; 2014 Jan; 110(2):375-83. PubMed ID: 24366294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor cells following first chemotherapy cycle: an early and strong predictor of outcome in patients with metastatic breast cancer.
    Martín M; Custodio S; de Las Casas ML; García-Sáenz JÁ; de la Torre JC; Bellón-Cano JM; López-Tarruella S; Vidaurreta-Lazaro M; de la Orden V; Jerez Y; Márquez-Rodas I; Casado A; Sastre J; Díaz-Rubio E
    Oncologist; 2013; 18(8):917-23. PubMed ID: 23873719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment.
    Giuliano M; Giordano A; Jackson S; Hess KR; De Giorgi U; Mego M; Handy BC; Ueno NT; Alvarez RH; De Laurentiis M; De Placido S; Valero V; Hortobagyi GN; Reuben JM; Cristofanilli M
    Breast Cancer Res; 2011 Jun; 13(3):R67. PubMed ID: 21699723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy.
    Magbanua MJM; Hendrix LH; Hyslop T; Barry WT; Winer EP; Hudis C; Toppmeyer D; Carey LA; Partridge AH; Pierga JY; Fehm T; Vidal-Martínez J; Mavroudis D; Garcia-Saenz JA; Stebbing J; Gazzaniga P; Manso L; Zamarchi R; Antelo ML; Mattos-Arruda L; Generali D; Caldas C; Munzone E; Dirix L; Delson AL; Burstein HJ; Qadir M; Ma C; Scott JH; Bidard FC; Park JW; Rugo HS
    J Natl Cancer Inst; 2021 Apr; 113(4):443-452. PubMed ID: 32770247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.